Control
Sep 16 2024 |
et al., AMB Express, doi:10.1186/s13568-024-01739-8 | Establishment of in-house assay for screening of anti-SARS-CoV-2 protein inhibitors |
| In Vitro study showing that curcumin, quercetin, gallic acid, and silymarin inhibit SARS-CoV-2 spike protein binding to the ACE2 receptor. Authors developed a novel immunofluorescent assay to screen potential inhibitors of the spike-ACE2 .. | ||
Jul 20 2022 |
et al., Phytotherapy Research, doi:10.1002/ptr.7537 | Evaluation of the efficacy of oral nano‐silymarin formulation in hospitalized patients with COVID‐19: A double‐blind placebo‐controlled clinical trial |
| 20% higher need for oxygen therapy (p=0.78) and 8% shorter hospitalization (p=0.5). RCT 50 hospitalized COVID-19 patients showing no significant difference in symptom resolution time or hospitalization duration with nano-silymarin treatment. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.